Efficacy of 5-hydroxytryptamine-3 (5-HT3) antagonists adjuvant therapy for moderate to severe obsessive–compulsive disorder: A systematic review and meta-analysis of randomized clinical trials

Author:

Eissazade Negin1,Mosavari Hesam1,Eghdami Shayan1,Boroon Mahsa2,Ashrafi Faria3,Shalbafan Mohammadreza2

Affiliation:

1. Iran University of Medical Sciences

2. Psychosocial Health Research Institute (PHRI), Iran University of Medical Sciences

3. Institute for Cognitive Science Studies

Abstract

Abstract Background: obsessive–compulsive disorder (OCD) is the fourth most common mental disorder, and selective serotonin reuptake inhibitors (SSRIs) are the cornerstone of its pharmacological treatment. About 40-60% of the cases are treatment-refractory, and this makes searching for second-line treatment necessary. 5-hydroxytryptamine-3 (5-HT3) antagonists are among the many medications that have been used in augmentation with SSRIs. Objectives: In this systematic review and meta-analysis, we assessed the efficacy of 5-HT3 receptor antagonists in augmentation with SSRIs in treating moderate to severe OCD. Methods: We searched PubMed, Web of Science, Scopus, Cochrane library, and Google Scholar for relevant trials published up to December 2022. The effect size was the mean difference in Yale-Brown obsessive compulsive scale (Y-BOCS) scores before and after receiving 5-HT3 receptor antagonist drugs in augmentation with SSRIs in moderate to severe OCD patients. Results: We included 6 randomized-controlled trails (RCTs) with 334 patients assessing the effect of the augmentation of SSRIs with ondansetron, granisetron, and tropisetron on treating moderate to severe OCD. Our results were in favor of the experimental group in total (Z=8.37, P<0.00001), in the compulsion subgroup (Z=5.22, P<0.00001), and in the obsession subgroup (Z=8.33, P<0.00001). They are well-tolerated, and have mild side effects and do not result in withdrawal. Conclusion: Augmentation of 5HT-3 antagonists with SSRIs can be beneficial in treating moderate to severe OCD. Further multi-center trials under adequate conditions in longer periods are needed to help come up with a comprehensive action plan.

Publisher

Research Square Platform LLC

Reference50 articles.

1. Obsessive-compulsive disorder;Veale D;BMJ,2014

2. Obsessive–compulsive disorder: an integrative genetic and neurobiological perspective;Pauls D;Nat Rev Neurosci,2014

3. Clinical practice guidelines for Obsessive-Compulsive Disorder;Janardhan Reddy YC;Indian J Psychiatry.,2017

4. The psychopharmacology of obsessive-compulsive disorder implications for treatment and pathogenesis;McDougle CJ;Psychiatr Clin North Am,1993

5. NICE. “Overview | Obsessive-Compulsive Disorder and Body Dysmorphic Disorder: Treatment | Guidance | NICE.” Nice.org.uk, NICE, 29 Nov. 2005, www.nice.org.uk/guidance/cg31.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3